DPP4 and metabolic dysfunction-associated steatotic liver disease: Anagliptin: In recent years, numerous studies were published which have shown the efficacy of anti-diabetic drugs like sodium-glucose co-transporter-2 (SGLT2) and dipeptidyl peptidase-4 (DPP4) inhibitors in preventing the progression of NAFLD to NASH [25-27].